Authors: Maria Diez Campelo Regina Garcia Delgado Ana Cristina Godoy Molias Jesus Feliu Sanchez
Publish Date: 2011/03/09
Volume: 28, Issue: 2, Pages: 10-15
Abstract
The management of myelodysplastic syndromes MDS in elderly patients is a significant clinical problem The therapeutic options range from observation alone for patients with lowrisk disease lenalidomide for patients with 5qsyndrome to 5azacytidine 5AZA for patients with higher risk of disease In this paper we summarize the clinical course of three patients with highrisk MDS treated with 5AZA as well as the management and supportive care measures for adverse events As expected based on available clinical trials data the agent resulted in clinical and hematological improvement in these patients with acceptable side effects 5AZA is an attractive option for elderly patients with highrisk MDS
Keywords: